Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Oral BTK Inhibitor Rilzabrutinib (PRN1008) in Moderate to Severe Pemphigus
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 13 Sep 2023
Price :
$35
*
At a glance
- Drugs Rilzabrutinib (Primary) ; Prednisone
- Indications Pemphigus; Pemphigus vulgaris
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms PEGASUS
- Sponsors Principia Biopharma
- 01 Jan 2023 This trial has been discontinued in Italy, according to European Clinical Trials Database record.
- 03 Mar 2022 This trial has been completed in Greece, according to European Clinical Trials Database record.
- 02 Feb 2022 This trial has been completed in Croatia (End Date: 17 Dec 2021), according to European Clinical Trials Database record.